Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events

BackgroundTarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC). However, its post-marketing safety profile in routine practice remains incompletely characterized.MethodsWe conducted a retrospective pharmacovigilance...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Yingyong Ou, Xianxian Zhong, Mei Mei, Xiao Gu, Shanshan Luo, Gaoyu Chen, Xuqin Xie, Desheng Sun
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2026-06-01
Seri Bilgileri:	Frontiers in Pharmacology
Konular:	cytokine release syndrome FAERS immune effector cell-associated neurotoxicity syndrome pharmacovigilance shap tarlatamab
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1844248/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!